Should investors bet on large-cap pharma stocks? Alok Agarwal answers

economictimes.indiatimes.com:

«I remain upbeat and positive about the changes. Yes, at the same time, there are increasingly green shoots visible in the lower end of most consumer products, and this change is coming at the right time, possibly indicating better growth ahead of us,» says Alok Agarwal, Alchemy Capital.

What is your take on the commentary from Rajiv about the category breaker this particular CNG bike could become? It is the first of its kind, and clearly, you have to give full marks for that. The stock is higher by 2%. But what does it do to this category, this value category? The 85,000-95,000 per unit value category was ignored by everybody, as all the players were focusing on premiumization. Can it revitalize that space and get volumes back?
Alok Agarwal: We have been seeing a K-shaped recovery all through, especially after COVID, and that was reflected in automobiles and two-wheelers as well. But at the same time, one of the most efficient companies is coming forward with CNG bikes. I think it is a welcome step, a welcome move. It is a calculated move as well. They have also showcased how they have changed things in the past. So, I remain upbeat and positive about the changes. Yes, at the same time, there are increasingly green shoots visible in the lower end of most consumer products, and this change is coming at the right time, possibly indicating better growth ahead of us.

The other area I would like your opinion on is large-cap pharma. Today is the second day we are seeing even Laurus and other mid-tier ones coming back.